3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD) in adults
- 6 July 2022
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2022 (7)
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up studyJournal of Psychopharmacology, 2012
- The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyJournal of Psychopharmacology, 2010
- Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administrationSocial Neuroscience, 2009
- Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing populationJournal of Psychopharmacology, 2006
- The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)Pharmacological Reviews, 2003
- An Exploration of the History and Controversies Surrounding MDMA and MDAJournal of Psychoactive Drugs, 2001
- 3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H215O]-PET in Healthy HumansNeuropsychopharmacology, 2000
- Pharmacology of MDMA in HumansAnnals of the New York Academy of Sciences, 2000
- Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observationsBehavioural Brain Research, 1995
- Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sitesEuropean Journal of Pharmacology, 1988